Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with significant implications in extending patient survival and advancing closer to the goal of a cure, especially in areas of immunotherapy such as chimeric antigen receptor T cells, bispecific T cell engager antibodies, antibody drug conjugates, newer generations of monoclonal antibodies, and small molecule inhibitor and modulators. This review provides an update of current myeloma therapeutics in active preclinical and early clinical development and discusses the mechanism of action of several classes of novel therapeutics.

Automated summary

The field of multiple myeloma therapy has seen remarkable innovation in recent years, with new therapies on the horizon that have the potential to extend patient survival and move closer to a cure. These emerging therapies include immunotherapy approaches such as chimeric antigen receptor T cells and bispecific T cell engager antibodies, as well as newer generations of monoclonal antibodies and small molecule inhibitors.